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Clostridium difﬁ  cile, the most commonly recognized 
diarrheagenic pathogen among hospitalized persons, 
can cause outpatient diarrhea. Of 1,091 outpatients with 
diarrhea, we found 43 (3.9%) who were positive for C. 
difﬁ  cile toxin. Only 7 had no recognized risk factors, and 3 
had neither risk factors nor co-infection with another enteric 
pathogen. 
I
n the United States, ≈375 million episodes of acute 
diarrhea occur annually (1). Among hospitalized 
persons, toxin-producing Clostridium difﬁ  cile is a primary 
diarrheagenic pathogen, usually as a consequence of 
normal bowel ﬂ  ora distortion caused by antimicrobial drug 
therapy (2,3). C. difﬁ  cile infection (CDI) complicates and 
prolongs hospital stays, leading to increases in health care 
costs, illness, and death. Recent reports suggest increases 
in community-onset CDI among persons without recent 
antimicrobial drug treatment or hospitalization. We 
describe a prospective evaluation of CDI in persons with 
diarrhea who visited emergency departments (EDs) and 
ambulatory primary care clinics in Baltimore, Maryland, 
and New Haven, Connecticut, and identify microbiologic 
causes and epidemiologic characteristics of diarrhea. This 
report highlights cases of outpatient CDI, identiﬁ  es factors 
associated with infection, and describes molecular strain 
characterization.
Patients seeking medical attention for community-
onset diarrheal illnesses were enrolled from May 2002 
through September 2004 in the EDs and ambulatory clinics 
at Yale–New Haven Hospital (New Haven, CT, USA) 
and from May 2002 through July 2007 at EDs and clinics 
afﬁ  liated with the University of Maryland (Baltimore, MD, 
USA) (4).
Informed consent for stool sample collection, initial 
and follow-up patient interviews, and medical records 
review was obtained from primarily urban and suburban 
residents, or parents/guardians for minors, who sought 
treatment for self-identiﬁ  ed primary or secondary diarrhea. 
This research was approved by the institutional review 
boards at all participating institutions.
Participants were interviewed at outpatient clinics to 
assess health status, symptoms, and potential exposures 
to enteric pathogens, and at follow-up to determine the 
duration of diarrhea, whether treatment was administered, 
or whether hospitalization resulted from the initial visit. 
Stool samples collected during the visit or provided within 
48 h and kept cool were homogenized and transferred into 
multiple vials for storage at –80°C.
An outpatient CDI case was deﬁ  ned in an outpatient 
with diarrhea whose stool was positive for C. difﬁ  cile 
toxins by enzyme immunoassay (TOX A/B II ELISA; 
TechLab, Blacksburg, VA, USA). Presumptive non–health 
care–associated (NHA) CDI was deﬁ  ned by the absence of 
an overnight stay at an inpatient healthcare facility over the 
previous month.
Traditional risk factors for CDI that were investigated 
included antimicrobial drug use within the past month, age 
>65 years, serious underlying illness/weakened immune 
system, history of bowel or ulcer surgery, colon disease, 
previous CDI, and recent hospitalization. Statistical 
analysis was done by using SAS version 9.2 (SAS Institute, 
Inc., Cary, NC, USA). All p values reported are 2-sided, 
with no correction for multiple comparisons; p<0.05 was 
considered signiﬁ  cant.
C. difﬁ  cile toxin–positive stool specimens, in 1-mL 
aliquots, were shipped frozen to the Centers for Disease 
Control and Prevention (Atlanta, GA, USA) anaerobe 
laboratory for culturing by direct inoculation onto 
cycloserine cefoxitin fructose agar (CCFA) or ethanol 
shock, followed by CCFA inoculation. Cultures were 
incubated for 48–72 h at 35°C under anaerobic conditions 
and examined for characteristic yellow-green ﬂ  uorescence 
under long-wave ultraviolet light and CCFAp-cresol odor. 
C. difﬁ  cile colonies were conﬁ  rmed with indole (negative) 
and PRO disk (positive; Remel, Lenexa, KS, USA) tests.
Pulsed-ﬁ   eld gel electrophoresis was performed 
on  C. difﬁ  cile genomic DNA digested with SmaI, and 
toxinotyping was performed (5). Binary toxin was assayed 
by PCR for cdtB (6). Deletions in tcdC were detected (7).
C. difﬁ  cile toxin tests were performed on 1,091/1,197 
stool specimens; 43 (3.9%) of these case-patients met the 
case deﬁ  nition for outpatient CDI. The mean age of these 
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case-patients was 43.7 years (range 4 months–88 years). 
Outpatient CDI case-patients were younger at Yale because 
a signiﬁ  cantly greater proportion of toxin-positive children 
were recruited at Yale (45.5%) than at the University of 
Maryland (15.6%) (p = 0.04). The 43 outpatient CDI case-
patients included 5 infants <1 year of age, 5 children 1–18 
years of age, 23 adults 19–64 years of age, and 10 adults 
>65 years of age; 21 were Caucasian, 18 were African 
American, and 4 were of other or unknown race/ethnicity 
(22 male and 21 female case-patients).
Most case-patients (36/43, 83.7%) had a recognized 
underlying risk factor. Twenty-seven (62.8%) had 
received systemic antimicrobial drugs, including 
ciproﬂ  oxacin,  gaitiﬂ   oxacin, amoxicillin, ampicillin/
sulbactam, piperacillin/tazobactam, cefpodoxime, 
vancomycin, clindamycin, metronidazole, erythromycin, 
or trimethoprim/sulfamethoxazole within the preceding 
month; 14 (32.6%) had been hospitalized; and 15 (34.9%) 
had chronic illnesses or had undergone bowel surgery that 
potentially affect immune status or gastrointestinal function 
(Table 1). Two persons, 1 with AIDS and 1 who underwent 
a previous bowel resection for diverticulitis, had been 
treated in the past month for CDI. Only 7 (16.3%) patients 
had NHA-CDI infections without identiﬁ  ed risk factors; 3 
were infants (<1 year), 1 was a child (1–18 years), 3 were 
adults (19–64 years), and none were elderly (>65 years) 
(Table 2).
The 43 outpatient CDI case-patients were compared 
with the other 1,048 persons in which C. difﬁ  cile toxin had 
not been detected. Persons with CDI were, on average, 
signiﬁ  cantly older than others with diarrhea, 43.7 years vs. 
29.2 years, respectively (p<0.01). Outpatient CDI case-
patients were more likely than C. difﬁ  cile–negative patients 
to have medical or surgical conditions (34.9% vs.16.8%, 
p<0.001), been recently hospitalized (32.6% vs. 8.8%, 
p<0.001), or to have used antimicrobial drugs (62.8% vs. 
22.0%, p<0.001).
Co-infections with other enteric pathogens were 
common among CDI case-patients, including C. 
perfringens (3), rotavirus (5), norovirus (3), sapovirus (2), 
and 1 each with hookworm, Bacillus cereus, astrovirus, and 
adenovirus. The likelihood of co-infection was similar in 
patients with (12/36 [33.3%]) and without (3/7 [42.9%]) 
risk factors (p>0.1).
Of 43 C. difﬁ  cile toxin–positive stools initially tested, 
39 stool samples were submitted to the Centers for Disease 
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Table 1. Patient risk factors for CDI compared with those of other patients with diarrhea without CDI, Maryland and Connecticut, USA, 
20022007* 
Risk factor 
No. (%) patients with 
CDI, n = 43
No. (%) patients with diarrhea 
but not CDI, n = 1,048  p value†
Illnesses potentially affecting immune status
  Lupus 1 (2.3)  4 (0.4)  0.06
  Cancer under active treatment 3 (7.0)  40 (3.8)  0.30
 HIV/AIDS 2 (4.7)  43 (4.1)  0.86
  History of organ transplant 2 (4.7)  22 (2.1)  0.26
  Chronic obstructive pulmonary disease (on prednisone) 1 (2.3)  NA NA
Illnesses potentially affecting gastrointestinal function
  Crohn disease 0 (0)  14 (1.3)  0.45
 Ulcerative  colitis 1 (2.3)  19 (1.8)  0.81
Prior bowel or ulcer surgery 6 (14.0)  69 (6.6)  0.06
Any medical or surgical condition 15 (34.9)  176 (16.8)  0.002 
Hospitalized within prior month 14 (32.6)  92 (8.8)  <0.001 
Antimicrobial drug therapy within prior month 27 (62.8)  231 (22.0)  <0.001 
No hospitalization or antimicrobial drug therapy within prior 
month and no predisposing condition
7 (16.3)  698 (66.6)  <0.001 
*CDI, Clostridium difficile infection; NA, not available. 
†Uncorrected Ȥ
2.
Table 2. Characteristics of CDI case-patients who had no identified risk factors, Maryland and Connecticut, USA, 20022007* 
Patient ID Recruitment site Age/sex Race/Ethnicity Other medical conditions Co-infections
1 Maryland 62 y/M White Hypertension, GERD, COPD/asthma, 
depression/anxiety
2 Maryland 6 mo/M White Reflux C. perfringens,
rotavirus
3 Yale 20 mo/M Hispanic None  Norovirus
4 Yale 5 mo/M White None 
5 Yale 28 y/F Black None  Rotavirus
6 Yale 34 y/F Hispanic Polycystic ovary disease, diabetes, GERD
7 Yale 4 mo/M Hispanic None  Norovirus
*CDI, Clostridium difficile infection; GERD, gastroesophageal reflux disease; COPD, chronic obstructive pulmonary disease. Control and Prevention for anaerobic culture and C. 
difﬁ  cile was isolated from 31 samples. Binary toxin was 
identiﬁ  ed in 12 (38.7%). Pulsed-ﬁ  eld gel electrophoresis 
identiﬁ  ed 15 different types (Figure). No associations were 
found between risk factors, including age, and strain or 
toxinotype (data not shown).
NHA-CDI has been recognized for >12 years, and recent 
reports suggest that disease occurs without patient’s known 
exposure to antimicrobial drugs or other previously identiﬁ  ed 
risk factors (2,8–13). Although we found a proportion of C. 
difﬁ  cile–positive diarrheal stools similar to that of 2 other 
recent prospective studies that used conﬁ  rmatory  culture 
(i.e., 1.5%–3.9%) for outpatient CDI (7,13,14), we also 
found a lower proportion of outpatient CDI cases without 
recognized risk factors of recent hospitalization, chronic 
medical conditions, recent antimicrobial drug exposure, or 
co-infection than did those studies.
One limitation of our study was using retrospective 
self-reporting for assessment of hospitalizations or 
antimicrobial drug use in the previous month, which 
potentially can result in recall bias. Also, antimicrobial 
drug therapy was assessed for only 4 weeks before diarrhea 
onset; exposure to antimicrobial drugs for a period longer 
than 1 month before patient seeks treatment may present 
a risk for CDI. In addition, this study was conducted at 2 
urban centers in the eastern United States and may not be 
generalizable to other locations or clinical settings. Finally, 
although enzyme immunoassay detection for C. difﬁ  cile 
was the standard of care at the time of the study, it is now 
considered too insensitive to be used as a stand-alone 
diagnostic test (15).
In summary, we detected toxigenic C. difﬁ  cile in a 
similar proportion of patients to those reported in other 
studies of CDI. However, all but 3 patients had either 
known risk factors for CDI or other pathogens potentially 
responsible for their illness; 1 was <1 year of age. C. difﬁ  cile 
isolates responsible for outpatient CDI are genetically 
diverse. An evolving picture of widespread, frequent CDI 
among outpatients without risk factors should be tempered 
by these ﬁ  ndings. 
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